CClinicalTrials.gg
TerminatedNCT01632943HTN-IndiaUpdated Feb 7, 2017

Single-arm Study of Symplicity™ Renal Denervation System in Patients With Uncontrolled HyperTensioN in India

An interventional study of Symplicity renal denervation system in Adults With Uncontrolled Hypertension, sponsored by Medtronic Vascular. Terminated at 1 site in India. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-02-07.

Sponsored by Medtronic Vascular · Not applicable, Interventional, and Treatment

Why this study was terminated
Study Enrollment was stopped pending review of another study in the same therapeutic area.
Phase
Not applicable
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study is to evaluate efficacy and safety of renal denervation in the treatment of uncontrolled hypertension. This study will enroll a minimum of 40 and a maximum of 45 subjects. The study will be conducted at up to 8 actively enrolling investigational sites. The primary endpoint is change in Office Systolic Blood Pressure from baseline to 6 months post-procedure.

Read the detailed description

Estimated enrollment Start: May 2013 (estimated 90 day duration) Estimated last follow-up: September 2013 Follow-Up Duration: Subjects in the intent-to-treat population will be followed from enrollment through 6 months ±14 days for the effectiveness and safety endpoints

02

Conditions studied

  • Adults With Uncontrolled Hypertension

Browse trials for

Keywords

  • Uncontrolled Hypertension
03

In context

Hypertension

6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.

This study's enrollment of 14 is below the median of 90 across 4,995 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

Medtronic Vascular is the lead sponsor of 58 studies on the registry; 7 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Individual is 18 and 80 years old at time of treatment.
  2. Individual is receiving a stable medication regimen including 3 or more anti-hypertensive medications of different classes, of which one must be a diuretic that is expected to be maintained without changes for at least 6 months.
  3. Individual has an office systolic blood pressure of 160 mm Hg based on an average of 3 blood pressure readings measured at screening visits
  4. Individual or legally authorized representative agrees to have all study procedures performed, and is competent and willing to provide written, informed consent to participate in this clinical study.

Exclusion criteria

Exclusion Criteria:

  1. Individual has renal artery anatomy that is ineligible for treatment including:

    • Main renal arteries with less than 4 mm diameter or with less than 20 mm treatable length
    • Multiple renal arteries where the main renal artery is estimated to supply less than 75 percent of the kidney.
    • Renal artery stenosis more than 50 percent or renal artery aneurysm in either renal artery.
    • A history of prior renal artery intervention including balloon angioplasty or stenting.
  2. Individual has an estimated glomerular filtration rate of less than 45mL per min per 1.73m2, using the MDRD calculation.
  3. Individual has had more than 1 in-patient hospitalization for a hypertensive crisis within the past year.
  4. Individual has type 1 diabetes mellitus.
  5. Individual has had 1 or more episodes of symptomatic orthostatic hypotension within the past year or during the screening process.
  6. Individual requires chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea.
  7. Individual has primary pulmonary hypertension.
  8. Individual has known secondary causes of hypertension, such as untreated pheochromocytoma, Cushing's Disease, coarctation of the aorta, hyperthyroidism, or hyperparathyroidism.
  9. Individual has experienced a myocardial infarction, unstable angina pectoris, syncope, or a cerebrovascular accident within 6 months of the screening period, or has widespread atherosclerosis, with documented intravascular thrombosis or unstable plaques.
  10. Individual has a scheduled or planned surgery or cardiovascular intervention in the next 6 months.
  11. Individual has a condition that would prohibit or interfere with ability to obtain an accurate blood pressure measurement using the protocol specified automatic blood pressure monitor
  12. Individual has severe cardiac valve stenosis for which, in the opinion of the Investigator, a significant reduction of blood pressure is contraindicated.
  13. Individual has any serious medical condition, which in the opinion of the investigator, may adversely affect the safety and/or effectiveness of the participant or the study
  14. Individual is pregnant, nursing or planning to be pregnant.
  15. Individual has a known, unresolved history of drug use or alcohol dependency, lacks the ability to comprehend or follow instructions, or would be unlikely or unable to comply with study follow-up requirements.
  16. Individual is currently enrolled in another investigational drug or device trial. For the purposes of this protocol, participants involved in extended follow-up trials for products that were investigational but are currently commercially available are not considered enrolled in an investigational trial.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Symplicity renal denervation system

    Device: Symplicity renal denervation system

Interventions

  • DeviceSymplicity renal denervation system

    Previous research has shown that disrupting the nerves of the kidney may successfully decrease blood pressure. A less invasive approach to disrupting these nerves is to apply a brief high temperature near the nerves (renal denervation). This can now be done with an experimental medical device called the Symplicity renal denervation system. The System includes a catheter that is inserted into your blood vessels and an RF-generator.

06

What researchers measure

Primary outcomes

  1. Efficacy: Change in Office Systolic Blood Pressure from baseline to 6 months post-procedure

    Time frame: 6 months post procedure

Secondary outcomes

  1. Safety: Incidence of Major Adverse Events (MAE),through 6 months post-procedure

    Time frame: 6 months post procedure

07

Study locations

1 site
  • Care Institute of Medical Sciences
    Ahmedabad, Gujarat 380060, India
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01632943
Lead sponsor
Medtronic Vascular
Collaborators
Medtronic
Responsible party
Sponsor
First posted
Jul 4, 2012
Start date
Oct 2013
Primary completion
Nov 2014
Completion
Dec 2014
Last update
Feb 7, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion